Radiographic Evaluation of Medication-Related Osteonecrosis of the Jaw (MRONJ) With Different Primary Cancers and Medication Therapies

被引:1
|
作者
Muttanahally, Kavya Shankar [1 ]
Tadinada, Aditya [2 ]
机构
[1] Univ Nebraska Med Ctr, Dept Adult Restorat Dent Oral & Maxillofacial Rad, Lincoln, NE 68588 USA
[2] Univ Connecticut, Dept Oral & Maxillofacial Radiol, Farmington, CT USA
关键词
cone beam computed tomography (cbct); primary cancer; osteonecrosis; mronj; antiresorptive; BISPHOSPHONATE-RELATED OSTEONECROSIS; SURGEONS POSITION PAPER; AMERICAN ASSOCIATION;
D O I
10.7759/cureus.42830
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a condition that affects the jaws and is characterized by exposed bone in the oral cavity that persists for more than eight weeks despite treatment. Additional criteria include that the patient should have a current or past history of antiresorptive drugs and/or in combination with antiangiogenic drugs, absence of metastasis, and no previous radiotherapy to the affected area. The radiographic features of MRONJ in most instances do not have any specific radiographic features. This is because standard radiographs usually show no stark abnormalities in the early stages of the disease. Objective: The study aimed to evaluate if any specific radiographic patterns are associated with primary cancers and between medications.Materials and methods: The study is an observational case series. A total of 50 cases of possible osteonecrosis from June 2010 to June 2013 archives of the Department of Oral and Maxillofacial Radiology were assessed. Based on the history, 12 cases that had a history of medication use that could lead to medication-related osteonecrosis of the jaw (MRONJ) were selected. Cone beam computed tomography (CBCT) scans of these 12 cases were evaluated using the CBCT reconstruction program InVivo Dental version 6 (Anatomage Inc., San Jose, CA, USA). The number of areas showing sequestration, the pattern of osteonecrosis, and the extent were assessed. Primary cancer and the type of medication were also assessed to identify if certain cancers or drugs showed any distinctive pattern of osteonecrosis. Reconstructed panoramic images and true three-dimensional (3D) multi-planar images were assessed to study the condition. An oral and maxillofacial radiology resident in training and a board-certified oral and maxillofacial radiologist assessed the images.Results: Radiographic findings varied among the 12 cases and included generalized sclerosis, osteosclerosis with widened periodontal ligament (PDL) space, bony sequestra, and bony necrosis. However, no specific or distinctive radiographic patterns were observed in any of the cases, regardless of the type of primary cancer or medication used.Conclusion: It is challenging to radiographically distinguish between MRONJ cases with different primary cancer and/or medication. Future directions: Future studies should include evaluating larger samples with varying primary cancers and medications and combination drug therapies. Cases in an advanced stage of MRONJ do not have distinctive features due to extensive destruction and superimposed infection; it may be valuable to evaluate patients in the early stages of MRONJ to better understand distinguishing radiographic patterns specific to certain primary cancers or medications.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ)
    Yan, Ran
    Jiang, Ruixue
    Hu, Longwei
    Deng, Yuwei
    Wen, Jin
    Jiang, Xinquan
    INTERNATIONAL JOURNAL OF ORAL SCIENCE, 2022, 14 (01)
  • [22] Current Trends in Adjuvant Therapies for Medication-Related Osteonecrosis of the Jaw
    Shim, Gyu-Jo
    Ohe, Joo-Young
    Yoon, Young-Jae
    Kwon, Yong-Dae
    Kim, Deog-Yoon
    APPLIED SCIENCES-BASEL, 2022, 12 (08):
  • [23] Medication-Related Osteonecrosis of the Jaw (MRONJ): A Review of Pathophysiology, Risk Factors, Preventive Measures and Treatment Strategies
    AlRowis, Raed
    Aldawood, Abdulmalik
    AlOtaibi, Mohammed
    Alnasser, Essam
    AlSaif, Ibrahim
    Aljaber, Abdullah
    Natto, Zuhair
    SAUDI DENTAL JOURNAL, 2022, 34 (03) : 202 - 210
  • [24] Teriparatide for the Treatment of Medication-Related Osteonecrosis of the Jaw
    Chopra, Kirti
    Malhan, Namrita
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (04) : E469 - E477
  • [25] The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ)
    Miranda, Michele
    Gianfreda, Francesco
    Raffone, Carlo
    Antonacci, Donato
    Pistilli, Valeria
    Bollero, Patrizio
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [26] Evaluation of Medication-Related Osteonecrosis of the Jaw (MRONJ) in Terms of Staging and Treatment Strategies by Dental Students at Different Educational Levels
    Heimes, Diana
    Mark, Nicolas Alexander
    Kuchen, Robert
    Pabst, Andreas
    Becker, Philipp
    Kyyak, Solomiya
    Thiem, Daniel G. E.
    Schulze, Ralf
    Kaemmerer, Peer W.
    MEDICINA-LITHUANIA, 2023, 59 (02):
  • [27] Fat Graft in Surgical Treatment of Medication-Related Osteonecrosis of the Jaws (MRONJ)
    De Cicco, Davide
    Tartaro, Gianpaolo
    Colella, Giuseppe
    Dell'Aversana Orabona, Giovanni
    Santagata, Mario
    Ferrieri, Ivo
    Troiano, Antonio
    Stagliano, Samuel
    Volgare, Andrea Salvatore
    D'Amato, Salvatore
    APPLIED SCIENCES-BASEL, 2021, 11 (23):
  • [28] Medication-related Osteonecrosis of the Jaw: A Review
    AlDhalaan, Nouf A.
    BaQais, Asma
    Al-Omar, Ahmad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (02)
  • [29] Royal Jelly as a Therapeutic Intervention in Medication-Related Osteonecrosis of the Jaw (MRONJ): An Animal Model Study
    Topan, Cihan
    Bilge, Suheyb
    Demirbas, Ahmet Emin
    Agyuz, Guerkan
    Kara, Ayca
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2025, : 232 - 240
  • [30] Management of Medication-Related Osteonecrosis of the Jaw
    Williams, William Bradford
    O'Ryan, Felice
    ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2015, 27 (04) : 517 - +